Literature DB >> 10918396

Chromosomes 1 and 5 harbor plasmacytoma progressor genes in mice.

A E Coleman1, T Ried, S Janz.   

Abstract

Mouse spectral karyotyping (SKY) was employed to analyze 29 primary BALB/c plasmacytomas (PCTs) for the presence of chromosomal aberrations that took place subsequent to the Myc-activating T(12F1;15D2) or T(6C1;15D2) translocations, the initiating oncogenic mutations in plasmacytomagenesis. Recurrent amplifications of chromosome (Chr) 1 (48% prevalence) and promiscuous non-reciprocal translocations of Chr 5 (52% prevalence) suggested the existence of important PCT progressor genes on bands 1B/C and 5F. The additional occurrence of sporadic aberrations (93% prevalence) most likely reflected the general instability of the PCT genome. This instability, however, was not consistent, as two PCTs lacked secondary cytogenetic changes detectable by SKY. Our findings led us to conclude that BALB/c PCTs show a remarkably similar degree of cytogenetic heterogeneity to human multiple myeloma, despite being genetically defined (inbred mouse strain) and uniformly initiated (deregulation of Myc). Published 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10918396     DOI: 10.1002/1098-2264(2000)9999:9999<::aid-gcc1009>3.0.co;2-c

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  2 in total

1.  Anaplastic plasmacytomas: relationships to normal memory B cells and plasma cell neoplasms of immunodeficient and autoimmune mice.

Authors:  Chen-Feng Qi; Dong-Mi Shin; Zhaoyang Li; Hongsheng Wang; Jianxum Feng; Janet W Hartley; Torgny N Fredrickson; Alexander L Kovalchuk; Herbert C Morse
Journal:  J Pathol       Date:  2010-05       Impact factor: 7.996

Review 2.  Germline Risk Contribution to Genomic Instability in Multiple Myeloma.

Authors:  Siegfried Janz; Fenghuang Zhan; Fumou Sun; Yan Cheng; Michael Pisano; Ye Yang; Hartmut Goldschmidt; Parameswaran Hari
Journal:  Front Genet       Date:  2019-05-08       Impact factor: 4.599

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.